Genmab Continues Share Buy-back Program in April 2025

Genmab ( (GMAB) ) has shared an update.

On April 28, 2025, Genmab A/S announced the continuation of its share buy-back program, initially launched on March 25, 2025, to repurchase up to 2.2 million shares. The program, aimed at reducing capital and fulfilling commitments under the Restricted Stock Unit program, saw transactions executed between April 21 and April 25, 2025, accumulating a total of 76,427 shares bought back, with the program expected to conclude by July 10, 2025. This strategic move is in line with the company’s financial management and regulatory compliance under the EU’s Safe Harbour Regulation, potentially impacting its market positioning and shareholder value.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s strong financial performance and robust earnings call results, along with a relatively attractive valuation, contribute positively to its stock score. The technical analysis shows some caution due to potential overbought conditions, and while the dependency on key products is a minor concern, the company’s strategic investments and guidance for future growth are promising. Overall, Genmab is well-positioned for sustained growth in the biotechnology sector.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company leverages next-generation antibody technology platforms and translational sciences to create a proprietary pipeline, including bispecific T-cell engagers and antibody-drug conjugates, aiming to transform the lives of patients with cancer and other serious diseases by 2030.

YTD Price Performance: -1.95%

Average Trading Volume: 1,556,414

Technical Sentiment Signal: Buy

Current Market Cap: $12.59B

See more data about GMAB stock on TipRanks’ Stock Analysis page.